Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

Targeted therapies such as Cyclin Dependent Kinase 4 and 6 (CDK 4/6) inhibitors have improved the prognosis of metastatic hormone receptor (HR) positive breast cancer by combating the resistance seen with traditional endocrine therapy. The three approved agents currently in the market are palbocicli...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Mridula A., Qureshi, Sadaf, Omene, Coral, Toppmeyer, Deborah L., Ganesan, Shridar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313476/
https://www.ncbi.nlm.nih.gov/pubmed/34327137
http://dx.doi.org/10.3389/fonc.2021.693104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313476/
https://www.ncbi.nlm.nih.gov/pubmed/34327137
http://dx.doi.org/10.3389/fonc.2021.693104

Ejemplares similares